ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: Final appropriations for NCI Still Probably $875 Million; US-USR Drug Book Available

July 1, 1977

Women’s Caucus Calls For Wide Mammogram Payment

March 18, 1994

Central Europe Faces Massive Public Education, Environmental Problems, Related To Cancer

August 23, 1991

Chemical Society Designates Taxol, Camptothecin Discoveries Historic

April 25, 2003

Shuttle Vector Technology Concept Approved

February 28, 1986

Organizations Ask Senate To Increase NCI Appropriations, Order OMB To “Get Nose Out Of Tent”

May 2, 1986